{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:07:34Z","timestamp":1772107654450,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jbspin.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T12:45:55Z","timestamp":1460551555000},"page":"376-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["New therapeutic approach to hyperuricemia and gout in the light of recommendations"],"prefix":"10.1016","volume":"83","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.02.012_bib0125","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0130","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0135","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0140","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","article-title":"Hyperuricemia starts at 360 micromoles (6mg\/dL)","volume":"82","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jbspin.2013.12.001","article-title":"Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients","volume":"81","author":"Kienhorst","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0160","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0165","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jbspin.2012.01.012","article-title":"Usefulness of ultrasonography for gout","volume":"79","author":"Ottaviani","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0175","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2011.12.006","article-title":"GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n=1003)","volume":"79","author":"Liot\u00e9","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0180","first-page":"630","article-title":"Characteristics and management of gout patients in Europe: data from a large cohort of patients","volume":"19","author":"Richette","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0185","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jbspin.2016.02.012_bib0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbspin.2015.03.013","article-title":"Allopurinol and kidney function: An update","volume":"83","author":"Stamp","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2012.01.004","article-title":"Therapeutic perspectives on uricases for gout","volume":"79","author":"Garay","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrrheum.2012.216","article-title":"guidelines for gout management hold some surprises","volume":"9","author":"Bardin","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0205","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0210","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0215","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0220","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0225","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","article-title":"Prophylaxis for acute gout flares after initiation of urate-lowering therapy","volume":"53","author":"Latourte","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0230","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0235","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2013-203226","article-title":"Managing gout needs more than drugs: \u2018Il faut le savoir-faire, l\u2019Art et la maniere\u2019","volume":"72","author":"Liot\u00e9","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.02.012_bib0240","first-page":"S180","article-title":"Mise en place d\u2019un programme d\u2019\u00e9ducation th\u00e9rapeutique sur la goutte\u00a0: quels sont les besoins des patients goutteux\u00a0?","author":"Frazier-Mironer","year":"2014","journal-title":"Rev Rhum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T11:27:43Z","timestamp":1536838063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X16000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1297319X16000567"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.02.012","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapeutic approach to hyperuricemia and gout in the light of recommendations","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}